文献速递神经肿瘤

进展与挑战:高级别胶质瘤免疫治疗——随机临床试验的荟萃分析

Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials.
PubMed 文献 · J Neurooncol · 2024-09-04

该荟萃分析遵循PRISMA框架检索PubMed、Cochrane和Embase,纳入47项研究、3674例接受免疫治疗的高级别胶质瘤患者,评估免疫检查点抑制剂、病毒治疗和树突状细胞疫苗的疗效与安全性;树突状细胞疫苗总生存期最长,病毒治疗无进展生存期获益倾向对照组,不良事件以1-2级为主。

要点

  • 树突状细胞疫苗平均总生存期24.11个月,免疫检查点抑制剂11.05个月,病毒治疗11.79个月。
  • 免疫检查点抑制剂平均无进展生存期3.65个月;树突状细胞疫苗风险比中位数0.43(95%CI 29-64%)。
  • 病毒治疗无进展生存期倾向对照组;免疫检查点抑制剂与树突状细胞疫苗不良事件以1-2级为主。

核心结论

  • 免疫治疗对高级别胶质瘤具有潜在疗效,尤其是树突状细胞疫苗,但结果随治疗类型和患者个体特征差异显著。
  • 作者认为需要进一步随机对照试验以建立可靠的临床指南并优化治疗方案。

研究设计与样本

  • 遵循PRISMA框架的荟萃分析,检索PubMed、Cochrane和Embase,纳入47项研究、3674例接受免疫治疗的高级别胶质瘤患者。

主要发现

  • 免疫检查点抑制剂治疗患者平均总生存期为11.05个月,病毒治疗为11.79个月,树突状细胞疫苗为24.11个月。
  • 免疫检查点抑制剂平均无进展生存期为3.65个月。
  • 病毒治疗的无进展生存期倾向对照组,提示影响极小;树突状细胞疫苗显示无进展生存期显著改善,风险比中位数为对照组的0.43倍(95%CI 29-64%)。
  • 免疫检查点抑制剂不良事件主要为1级或2级,病毒治疗包含1例5级事件,树突状细胞疫苗不良事件以1级或2级为主。

局限性

  • 作者认为需要进一步随机对照试验以建立可靠的临床指南并优化治疗方案。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: High-grade gliomas (HGG) are the most aggressive primary brain tumors with poor prognoses despite conventional treatments. Immunotherapy has emerged as a promising avenue due to its potential to elicit a targeted immune response against tumor cells. OBJECTIVE: This meta-analysis aimed to evaluate the efficacy and safety of various immunotherapeutic strategies, including immune checkpoint inhibitors (ICI), virotherapy, and dendritic cell vaccines (DCV) in treating HGG. METHODS: Following the PRISMA framework, we searched PubMed, Cochrane, and Embase for studies reporting outcomes of HGG patients treated with immunotherapy. Key metrics included overall survival, progression-free survival, and treatment-related adverse events. RESULTS: We reviewed 47 studies, analyzing data from 3674 HGG patients treated with immunotherapy. The mean overall survival for patients treated with ICI was 11.05 months, with virotherapy at 11.79 months and notably longer for DCV at 24.11 months. The mean progression-free survival (PFS) for ICIs was 3.65 months. Virotherapy demonstrated a PFS favoring the control group, indicating minimal impact, while DCV showed substantial PFS improvement with a median of 0.43 times lower hazard compared to controls (95% CI: 29-64%). Adverse events were primarily Grade 1 or 2 for ICI, included a Grade 5 event for virotherapy, and were predominantly Grade 1 or 2 for DCV, indicating a favorable safety profile. CONCLUSION: Immunotherapy holds potential as an effective treatment for HGG, especially DCV. However, results vary significantly with the type of therapy and individual patient profiles. Further randomized controlled trials are necessary to establish robust clinical guidelines and optimize treatment protocols.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Palavani LB, Mitre LP, Camerotte R, et al. Advancements and challenges: immunotherapy therapy in high-grade glioma - a meta-analysis of randomized clinical trials. J Neurooncol. 2024. PMID: 39230804. doi:10.1007/s11060-024-04813-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。